Regentis Biomaterials
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here.
Money in, money out
What Regentis Biomaterials sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$13.6 million of profit last year.
Regentis Biomaterials vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Regentis Biomaterials | No profit yet | ||
 ResMed | 22.1× · Fair price | ||
 West Pharmaceutical Services | 58.8× · Expensive | ||
 Hologic | 30.0× · Fair price | ||
 Baxter International | No profit yet |
AI analysis
An AI analyst reads Regentis Biomaterials's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -1 | -2 | 1 | -9 | |
| -1 | -4 | 5 | -13 | |
| -1 | -4 | 5 | -14 | |
| -0.29 | -0.81 | 0.92 | – | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 2 | 0 | 0 | 8 |
| Cash | 1 | 0 | 0 | 7 |
| Total debt | 6 | 8 | 5 | 1 |
| Total liabilities | 44 | 46 | 42 | 3 |
| -42 | -46 | -41 | 5 | |
| 5 | 5 | 5 | – | |
| – | – | – | -177.2% | |
| 3.4% | 9.0% | -11.7% | -287.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -2 | -1 | -1 | -1 | |
| – | – | – | – | |
| -2 | -1 | -1 | -1 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| – | – | – | – |
Valuation
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Profitability
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Growth
- –
- –
- –
- –
- –
Financial health
- –
- –
- –
- –
- –
- –
- –
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
Not enough data
Questions about Regentis Biomaterials
Is Regentis Biomaterials a good stock to buy?
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Regentis Biomaterials AI analysis
What does Regentis Biomaterials do?
Regentis Biomaterials Ltd., a regenerative medicine company, develops tissue repair solutions that restore the health and enhance quality of life of patients. It is in Medical - Instruments & Supplies.
Does Regentis Biomaterials pay a dividend?
No. Regentis Biomaterials does not pay a dividend at the moment.
Is Regentis Biomaterials stock halal?
No. Regentis Biomaterials does not pass our halal screen: its cash and confirmed interest-bearing investments are 85% of its market value, at or above the 33% limit. How we check
How has Regentis Biomaterials stock done over the past year?
Down 83.6% over the past twelve months, to $1.23. It traded between $1.17 and $9.40 and is 86.9% below its high.
Who are Regentis Biomaterials's competitors?
The largest listed companies in the same industry are ResMed, West Pharmaceutical Services, Hologic and Baxter International. The peers table on this page compares their profit, growth and price with Regentis Biomaterials's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.